Samsung Biologics Reports Third Quarter 2022 Financial Results - Recorded consolidated revenue of KRW 873 billion in Q3’22
- Recorded consolidated operating profit of KRW 324.7 billion in Q3’22
- Started partial operations at Plant 4 within 23 months since groundbreaking as previously committed and launched two new development platforms
Incheon, S. Korea, Oct. 26, 2022 – Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization, released today its fiscal year 2022 third-quarter financial results, announcing that the company’s cumulative revenue in fiscal year 2022 surpassed KRW 2 trillion.
John Rim, CEO of Samsung Biologics, said: “This past quarter saw strong performance and growth due to a consistent momentum in signing new contracts, helping us meet client demand for integrated offerings and deliver long-term value. Not only have we delivered on our commitments by commencing GMP operations of Plant 4 within just 23 months from the start of its construction, we have also developed and launched our next-generation bio-technologies – S-DUAL™ and DEVELOPICK™ – which will help streamline and accelerate the antibody development process to save time and cost for our clients.”
THIRD QUARTER 2022 RESULTS
Samsung Biologics in the third fiscal quarter recorded a consolidated revenue of KRW 873 billion, operating profit of KRW 324.7 billion, and net profit of KRW 129.2 billion.